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OBJECTIVE: The objective of this systematic review is to determine what is the safety and 
efficacy of Tarenflurbil (R-flubiprofen) in mild to moderate Alzheimer’s Disease. 
 
STUDY DESIGN: Review of three English language primary studies published in 2007, 2008, 
and 2009. 
 
DATA SOURCES: Randomized, double-blind, placebo-controlled clinical trials comparing 
Tarenflurbil 800 mg BID to placebo were found using Ovid MEDLINE, PubMed, and Cochrane 
databases. 
 
OUTCOMES(S) MEASURED: Cognition was assessed by the Alzherimer’s Disease (AD) 
assessment scale cognitive subscale (ADAS-Cog).  Functional ability was assessed by the AD 
cooperative study activities of daily living scale (ADCS-ADL).  Global function was assessed by 
the clinician interview based impression of change plus caregiver input (CIBIC+) and by the 
clinical dementia rating sum of boxes (CDR-sb). Adverse effects were assessed by patient 
reports.  The combined most common adverse effects reported include any adverse effect, 
diarrhea, nausea, adverse GI events, dizziness, urinary tract infection, and other renal/urinary 
disorders. 
 
RESULTS: Green et al found that the Tarenflurbil and placebo groups did not differ in the 
change from baseline to 18 months.  Wilcock et al found that for mild AD, treatment with 800 
mg of Tarenflurbil was associated with a significantly lower rate of decline than was treatment 
with placebo in activities of daily living and global function. The difference between 800 mg 
Tarenflurbil and placebo group in cognitive decline was not significant.  For moderate AD, 
treatment with placebo was associated with a significantly lower rate of decline in global 
function than 800 mg of Tarenflurbil. Non-significant effects were recorded for activities of daily 
living and cognition.  All three trials found Tarenflurbil to be safe and tolerable. 
 
CONCLUSIONS: The studies reviewed demonstrate that Tarenflurbil is safe and well tolerated, 
but did not slow cognitive decline. Analysis of functional ability showed differences between 
mild and moderate AD.  In mild AD, Tarenflurbil had lower rates of decline in activities of daily 
living, however, had no significant effects in moderate AD.  Tarenflurbil showed improvement 
and/or maintenance in global function for both mild to moderate AD.   
 
KEY WORDS: Alzheimer’s Disease, Tarenflurbil, R-flubiprofen 
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INTRODUCTION 
 Alzheimer’s Disease (AD) is the most common cause of chronic dementia1, accounting 
for 60-80% of all dementia
2
.   The Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition (DSM-IV) characterizes AD by the development of multiple cognitive deficits 
manifested by both memory impairment and one or more of the following: aphasia, apraxia, 
agnosia, and disturbances in executive functioning
3
.  The cognitive deficits cause significant 
impairment in social and/or occupational functioning
3
.  The course is characterized by gradual 
onset and continuing cognitive decline
3
.  The effects do not occur exclusively during the course 
of delirium, during substance-induced or systemic conditions, or are due to other central nervous 
system conditions that cause progressive deficits in memory and cognition
3
.  
 The exact etiology of AD is unknown, but it is thought to be due to an imbalance between 
neuronal injury and repair
1
.  Factors such as free radical formation, vascular insufficiency, 
inflammation, head trauma, hypoglycemia, and aggregated beta amyloid protein may cause 
neuronal injury
1
.  Factors contributing to ineffective repair may include the presence of the 
apolipoprotein E gene, altered synthesis of amyloid precursor protein, and hypothyroidism
1
.  
Characteristic intracellular tau-containing neurofibrillary tangles and extracellular beta amyloid 
plaques are found in the brain.  Also, deficits in key neurotransmitters, particularly acetylcholine, 
are linked to the cognitive symptoms.  The greatest risk factor is advancing age (>65 years old).  
Other risk factors include female gender, family history, and head trauma. 
 Alzheimer’s Disease affects 5.3 million Americans2 making it a prominent concern for 
health care practitioners.  Patients with AD have more than three times as many hospital stays 
compared to other older adults
2
.  Cost of care also increases with coexisting AD; the total 
Medicare costs and Medicare costs for hospital care are almost three times higher for AD 
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patients than for other Medicare beneficiaries
2
.  The estimated annual total cost of caring for a 
single AD patient in an advanced stage is more than $50,000
4
.   
 As of yet, no treatment is available to prevent, cure, or cease the deterioration of brain 
cells in AD.  Current approved therapies offer minimal effects and variable success.  Existing 
regimens include the use of three approved cholinesterase inhibitors (Donezepil hydrochloride, 
Galantamine, and Rivastigmine tartrate) and one N-methyl-D-aspartate receptor blocker 
(Memantine).  Tarenflurbil offers a different mechanism of action than the current approved 
regimens.  Leading theories on the pathophysiology of AD implicate overproduction of amyloid 
beta peptide
5,6
.  Tarenflurbil is a selective amyloid beta peptide-lowering agent; therefore, 
Tarenflurbil may provide a safe and effective treatment option as mono or adjuvant therapy for 
patients with mild to moderate AD.   This paper evaluates three randomized controlled trials 
comparing the administration of Tarenfluribil to placebo group as treatment in mild to moderate 
AD.   
OBJECTIVE 
 The objective of this systematic review is to determine “what is the safety and efficacy of 
Tarenflurbil (R-flurbiprofen) in mild to moderate Alzherimer’s Disease?”. 
METHODS 
 A detailed literature search was conducted using Ovid MEDLINE, PubMed, and the 
Cochrane Database of Randomized Controlled Trials and Systematic Reviews.  The key words 
used were “Alzheimer’s Disease”, “Tarenflurbil”, and “R-flubiprofen”.  All articles selected 
were published in peer review journals.  The articles were selected based on relevance and the 
outcomes mattered to the patients (Patient Oriented Evidence that Matters, or POEMS).  The 
studies included were randomized, controlled, double-blind, placebo controlled trials with a 
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patient oriented outcome.  The studies excluded were articles published prior to year 2006.  The 
statistics reported or used included p-value, mean change from baseline, 95% Confidence 
Interval (CI), Relative Risk Increase (RRI), Absolute Risk Increase (ARI), Numbers Needed to 
Harm (NNH), Absolute Risk Reduction (ARR), and Numbers Needed to Treat (NNT).   
 Three randomized, controlled, double-blind, placebo controlled trials were chosen for this 
review.  The criteria for selection of studies included the following: The population were patients 
aged 55 years or older who had a Mini-Mental State Examination (MMSE) score of 15-26.  The 
intervention was the administration of Tarenflurbil.  Comparisons included the treatment group 
receiving 800 mg of Tarenflurbil two times per day compared to a placebo group.  Table 1 
includes the demographics of the included studies.  
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Table 1. Demographics of included studies 
Study Type #Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
7
Galasko, 
2007 
RCT, 
specifically a 
randomized 
double-blind, 
placebo-
controlled 
clinical trial 
16 55-80 MMSE score 
>27 with no sig 
medical illness; 
willing to 
restrict use of 
ASA to <100 
mg/d 
CI to LP; use of 
NSAIDs w/in 3 mo; 
insulin use; h/o peptic 
ulcer, EtOH abuse, 
head injury w/ LOC 
>1h, epilepsy; CA 
w/in 2 yrs; abnormal 
ECG, renal/hepatic 
function 
0 Tarenflurbil 
800 mg BID 
vs. placebo 
group for 3 
weeks 
5
Green, 
2009 
RCT, 
specifically a 
multicenter, 
randomized, 
double-blind, 
placebo-
controlled 
trial 
1642 >55 MMSE of 15-
26; Hachinski 
score <4; no h/o 
MR; adequate 
vision/hearing; 
caregiver visits 
≥ 4 d/wk who 
can also 
accompany 
clinic visits 
Evidence of epilepsy, 
focal brain lesion, 
psych/ renal/hepatic 
disorders; h/o head 
injury w/ LOC >1h, 
NSAID hyper-
sensitivity, peptic 
ulcers; recent chronic 
NSAID use; CA w/in 
2 yrs; uncontrolled 
cardiac conditions; 
anticoag use w/in 12 
wks; Memantine w/in 
30d 
603 Tarenflurbil 
800 mg BID 
vs. placebo 
group for 18 
months 
6
Wilcock, 
2008 
RCT, 
specifically a 
Phase II, 
multicenter, 
randomized, 
double-blind, 
placbo-
controlled, 
parallel 
group study 
141 >55 MMSE of 15-
26; Hachinski 
score <4; no h/o 
MR; adequate 
vision/hearing; 
caregiver visits 
≥ 4 d/wk who 
can also 
accompany 
clinic visits 
Evidence of epilepsy, 
focal brain lesion, 
psych/ renal/hepatic 
disorders; h/o head 
injury w/ LOC >1h, 
NSAID hyper-
sensitivity, peptic 
ulcers; recent chronic 
NSAID use; CA w/in 
2 yrs; uncontrolled 
cardiac conditions; 
anticoag use w/in 12 
wks; Memantine w/in 
30d 
28 Tarenflurbil 
800 mg BID 
vs. placebo 
group for 12 
months 
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OUTCOMES MEASURED 
 All outcomes measured were based on relevance to Patient Oriented Evidence that 
Matters (POEMS).  The primary outcomes measured were cognition, functional ability, and 
global function.  Secondary outcomes measured were adverse effects.  Cognition was assessed 
by the AD assessment scale cognitive subscale (ADAS-Cog).  Functional ability was assessed by 
the AD cooperative study activities of daily living scale (ADCS-ADL).  Global function was 
assessed by the clinician interview based impression of change plus caregiver input (CIBIC+) 
measured by improvement or no change and by the clinical dementia rating sum of boxes (CDR-
sb).  Adverse effects were assessed by patient reports and by detailed questioned asked at clinic 
visits or by telephone.  
RESULTS 
 Green et al assessed cognition and functional ability as continuous data.  The primary 
analysis was performed on changes from baseline to month 18 in total score for ADAS-Cog and 
ADCS-ADL.  The statistics included were mean change from baseline, 95% confidence interval 
(CI), and p-values.   Treatment comparisons were made by slope analysis of the ADAS-Cog and 
ADCS-ADL.  All efficacy analyses were performed using the intent-to-treat (ITT) population 
consisting of all participants who were randomized, had mild AD at screening, and received at 
least 1 dose of study medication.  The statistical analysis found that the Tarenflurbil and placebo 
groups did not differ in the change from baseline to 18 months.  The mean treatment difference 
for the ADAS-Cog score was 0.1 (95% CI -0.9 to 1.1; p=.86) (Table 2).  The mean treatment 
difference for the ADCS-ADL score was -0.5 (95% CI -1.9 to 0.9; p=0.48) (Table 3). 
 Wilcock et at assessed cognition, functional ability, and global function as continuous 
data.  The primary analysis was based on interaction between baseline score to month 12 and 
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treatment group for ADAS-Cog and ADCS-ADL.  The secondary analysis was made for CDR-
sb.  The statistics included were mean rate of change in points per year, 95% CI, effect size, 
defined as mean percentage difference in slopes, and p-vaue.  The ITT population was defined as 
all patients randomly assigned to treatment who received at least one dose of Tarenflurbil and 
who had at least one post-baseline efficacy measurement, or who discontinued the study because 
of adverse event before an efficacy assessment.  A positive result in analysis of the data required 
a statistically significant change in one measure of cognition (ADAS-Cog) and one measure of 
function (ADCS-ADL or CDR-sb).  For mild AD, treatment with 800 mg of Tarenflurbil was 
associated with a significantly lower rate of decline than was treatment with placebo in actives of 
daily living (ADCS-ADL 95% CI 0.33 to 7.62, effect size of 46.4%, p-value = 0.033) (Table 3) 
and global function (CDR-sb 95% CI -1.57 to -0.03, effect size of 33.7%, p-value = 0.042) 
(Table 4).  The difference between 800 mg Tarenflurbil and placebo group in cognitive decline 
was not significant (ADAS-Cog 95% CI -4.07 to 1.36, effect size of 33.7%, p-value = 0.327) 
(Table 2).  For moderate AD, treatment with placebo was associated with a significantly lower 
rate of decline in global function than was 800 mg of Tarenflurbil (CDR-sb 95% CI 0.82 to 4.03, 
effect size of -52%, p-value = 0.003) (Table 4).   Non-significant effects were recorded for 
activities of daily living and cognition (ADCS-ADL 95% CI -13.44 to 3.17, effect size of -
38.2%, p-value = 0.223 and ADAS-Cog 95% CI -4.13 to 5.67, effect size of -10.1%, p-value = 
0.756) (Table 2 and 3, respectively).  Effect sizes were not consistent across measures.  
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Table 2. Rate of change from baseline in primary efficacy outcome and comparison of 800 
mg Tarenflurbil with placebo measured by the ADAS-Cog scale. 
 95% CI Effect size p-value 
Green Mild to moderate -0.9 to 1.1 NR .86 
Wilcock Mild -4.07 to 1.36 33.7% .327 
Moderate -4.13 to 5.67 -10.1% .756 
NR = not reported in study 
 
Table 3. Rate of change from baseline in primary efficacy outcome and comparison of 800 
mg Tarenflurbil with placebo measured by the ADCS-ADL scale. 
 95% CI Effect size p-value 
Green Mild to moderate -1.9 to 0.9 NR .48 
Wilcock Mild .33 to 7.62 46.4% 0.033 
Moderate -13.44 to 3.17 -38.2% .223 
NR = not reported in study 
 
  Wilcock et al also assessed global function with dichotomous data using the CIBIC+ 
scale.   With the CIBIC+ scale, effects were measured as improvement or had no change.  The 
relative risk reduction (RRR) was calculated to be 63% and the absolute risk reduction (ARR) 
was calculated to be 12%.  The number needed to treat (NNT) was 9 (Table 4).    
Table 4. Summary of analysis of global function based on outcomes and NNT (CIBIT+) 
and rate of change from baseline over 12 months. 
  RRR ARR NNT 95%CI Effect size p-
value 
CIBIC+ Mild 63% 12% 9 NR 15% 0.208 
 Moderate -100% -0.21 -5* NR NR 0.070 
CDR-sb Mild NR NR NR -1.57 to -0.03 33.7% 0.042 
 Moderate NR NR NR 0.82 to 4.03 -52% 0.003 
NR = not reported in study 
*The negative value for NNT indicates that for every 5 participants taking the 800 mg Tarenflurbil there 
was one fewer patient who declined from the participant’s normal level of global function.  
 
 Adverse effects of all three studies were converted to dichotomous data.  The number of 
adverse events that occurred in the 800 mg Tarenflurbil treatment group determined the 
experimental event rate (EER).  The number of adverse events that occurred in the placebo-
controlled group determined the control event rate (CER).  The EER and CER were used to 
determine the relative risk increase (RRI) and absolute risk increase (ARI).  The numbers needed 
                                                                                     Viscount, Tarenflurbil and AD  10 
to harm (NNH) was then calculated by taking the inverse of the ARI (1/ARI).  NNH represents 
the number of patients that would need to take 800 mg of Tarenflurbil in order to cause one 
adverse event.   
Adverse effects included, but are not limited to, diarrhea, constipation, nausea, vomiting, 
dizziness, urinary tract infection, agitation, confused state, upper respiratory tract infection, 
headache, depression, and rash.  Table 5 describes the outcomes measured and NNH for the 
combined most common adverse events reported, which includes any adverse effect, diarrhea, 
nausea, any GI effect, dizziness, urinary tract infections, and renal/urinary disorders. 
For any adverse effect, Green et al found that 87.2% taking Tarenflurbil vs. 85% 
receiving placebo reported any adverse event, with a RRI of 2.4%, ARI of 2%, and NNH of 50; 
Wilcock et al found that 90% taking Tarenflurbil vs. 85% receiving placebo reported any adverse 
event, with a RRI of 5.8%, ARI of 5%, and NNH of 20.  Galasko et al found 66% of both the 
Tarenflurbil and placebo group reported any adverse event, therefore the RRI and ARI were 
found to be zero, and the NNH was therefore undetermined.  For diarrhea, Green et al found that 
8.3% taking Tarenflurbil vs. 7.3% receiving placebo reported diarrhea, with a RRI of 14%, ARI 
of 1%, and NNH of 100; Wilcock found that 10% of participants taking Tarenflurbil vs. 8% 
receiving placebo reported diarrhea, with a RRI of 25%, ARI of 2%, and NNH of 50.  For 
nausea, Green et al reported that 4.7% taking Tarenfluril vs. 5.8% taking placebo reported 
nausea, with a RRI of -19%, ARI of -1.1% and NNH of -91; Wilcock et al found that 10% taking 
Tarenflurbil vs. 6% receiving placebo reported nausea, with a RRI 67%, ARI of 4%, and NNH of 
25.  Galasko et al reported on all adverse gastrointestinal (GI) events finding that 33% taking 
Tarenflurbil vs. 42% taking placebo reported any GI event, with a RRI of -19.5%, ARI of -
0.08%, and NNH of -2.5.  For urinary tract infection (UTI), Green et al found that 12.9% taking 
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Tarenflurbil vs. 13.3% receiving placebo reported a UTI, with a RRI of -3%, ARI of -0.4%, and 
NNH of -250; Wilcock found that 7% taking Tarenflurbil vs. 8% receiving placebo reported a 
UTI, with a RRI of -13%, ARI of -1%, and NNH of -100.  Galasko et al reported on all 
renal/urinary disorders finding that no participants taking Tarenflurbil vs. 8% receiving placebo 
reported renal/urinary disorders, with a RRI of -100%, ARI of -8.3%, and NNH of 12. 
Table 5. Summery of outcomes measured and NNH for the combined most common 
adverse events of all studies presented. 
Adverse Event Study RRI ARI NNH 
Any adverse effect Green 2.4% 2% 50 
Wilcock 5.8% 5% 20 
Galasko 0% 0% 0 
Diarrhea Green 14% 1% 100 
Wilcock 25% 2% 50 
Adverse GI events Galasko -20% -8.2% -13% 
Nausea Green -19% -1.1% -91 
Wilcock 67% 4% 25 
Dizziness Green 49% 2.8% 36 
Wilcock 17% 1% 100 
Renal/urinary 
disorders 
Galasko -100% -8.3% 12 
Urinary tract 
infection 
Green  -3% -0.4% -250 
Wilcock -13% -1% -100 
*The negative value for NNH represents that for every number of participants taking 800 mg of 
Tarenflurbil there is one fewer adverse event. 
 
Green et al found that of the participants that discontinued, 95 in the placebo group vs. 
158 in the Tarenflurbil group discontinued due to adverse events. Wilcock et al reported that the 
most common types of adverse events leading to discontinuation were GI disorders, metabolism 
and nutritional disorders, and psychiatric disorders.  Galasko et al reported that no serious 
adverse events were found and that no significant differences in the number or nature of adverse 
events were reported across groups.  No subjects discontinued participation in the study because 
of adverse events.   
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DISCUSSION 
 The studies chosen for this review encountered certain limitations.  There were a high 
proportion of study participants taking co-medications, which may have had implications on 
outcomes.  The studies were also limited by a high discontinuation rate.  Green et al reported that 
269 participants (33%) discontinued from the placebo group, while 334 participants (40%) 
discontinued from the 800 mg Tarenflurbil group (p=0.006).  Wilcock et al reported that an equal 
number of participants discontinued from both the placebo and Tarenflurbil group (n=13 and 
n=13, respectively).   
 Green et al reported that the 800 mg Tarenflurbil dose might have been too low for a 
therapeutically relevant effect in humans.  Plasma concentrations of Tarenflurbil indicated that 
the compound was absorbed as expected, however, data indicated that a dose-dependent 
penetration of drug from plasma to cerebrospinal fluid was only 0.5% to 1%, indicating low 
brain penetration.   
CONCLUSIONS 
 The studies reviewed demonstrate that Tarenflurbil is safe and well tolerated, but did not 
slow cognitive decline.  Analysis of functional ability showed differences between mild and 
moderate AD.  In mild AD, Tarenflurbil had lower rates of decline in activities of daily living, 
however, had no significant effects in moderate AD.  Tarenflurbil showed improvement and/or 
maintenance in global function for both mild to moderate AD.   
 Baseline differences in disease severity (MMSE score of 15-26) and differences co-
medication use may have impacted the disease-modifying effect.  There is a clear distinction 
between effects of 800 mg Tarenflurbil on mild AD compared to moderate AD.  Future research 
should be aimed at controlling both baseline MMSE score and co-medication use.  In addition to 
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regards with co-medication use, further research should focus on differentiating Tarenflurbil as 
mono or adjunct therapy. 
 An ongoing study performed by Wilcock et al included a follow-on phase of an 
additional effect from 12-24 months of treatment with 800 mg Tarenflurbil.  Results indicated 
that patients with mild AD who were in the 800 mg Tarenflurbil group for 24 months had lower 
rates of decline for all three primary outcomes compared to patients who were in the placebo 
group and compared to patients in the 800 mg Tarenflurbil group for months 12-24 (all p < 
0.001).  Further research should be focused on lengthening duration of treatment with 800 mg 
Tarenflurbil in mild AD.  
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